Performance evaluation of the new fully automated human immunodeficiency virus antigen‐antibody combination assay designed for blood screening
- 11 January 2008
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 48 (4) , 584-593
- https://doi.org/10.1111/j.1537-2995.2007.01583.x
Abstract
BACKGROUND: Before the introduction of human immunodeficiency virus (HIV) combination assays, serologic diagnosis of HIV infection was performed with assays that detected either antibodies or p24 antigen. Owing to the capability to detect the early appearance of p24 antigen, combination assays that are designed for simultaneous detection of antibodies and antigen can significantly reduce the diagnostic window.STUDY DESIGN AND METHODS: Specificity and sensitivity of a commercially available HIV antigen‐antibody combination assay (Abbott PRISM; assay is not licensed by the FDA for use in the United States) were evaluated in a multicenter study by testing volunteer blood donors, hospitalized patients, seroconversion panels, and p24 antigen and HIV antibody subtype panels. Performance data were compared to a commercially available HIV combination assay and the PRISM HIV O Plus assay.RESULTS: Apparent specificity of 99.95 percent was observed in the donor population for the PRISM HIV antigen‐antibody combination assay, and better seroconversion sensitivity was demonstrated compared with another combination assay and the PRISM HIV O Plus assay. Analytical HIV antigen detection sensitivity averaged 33 pg per mL on the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) panel. Furthermore, comparable antigen sensitivity was demonstrated for 32 HIV‐1 group M subtype and group O panels. The PRISM HIV combination assay detected all HIV‐1 group M and O and HIV‐2 antibody–positive specimens evaluated.CONCLUSIONS: The PRISM HIV antigen‐antibody combination assay demonstrated a significant reduction of the window period for diagnosis of HIV infection. The assay demonstrated enhanced specificity and sensitivity along with broad subtype detection. The assay performance represents the “state‐of‐the art” technology for serologic blood screening of HIV infection.Keywords
This publication has 28 references indexed in Scilit:
- Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the NetherlandsTransfusion, 2006
- Screening of HIV infection: role of molecular and immunological assaysExpert Review of Molecular Diagnostics, 2006
- Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assaysJournal of Virological Methods, 2004
- Multicenter Evaluation of a New, Automated Enzyme-Linked Immunoassay for Detection of Human Immunodeficiency Virus-Specific Antibodies and AntigenJournal of Clinical Microbiology, 2004
- HIV seroconversionAIDS, 2003
- Multicenter Evaluation of a New Automated Fourth-Generation Human Immunodeficiency Virus Screening Assay with a Sensitive Antigen Detection Module and High SpecificityJournal of Clinical Microbiology, 2002
- Evaluation of a New Combined Antigen and Antibody Human Immunodeficiency Virus Screening Assay, VIDAS HIV DUO UltraJournal of Clinical Microbiology, 2002
- Seven Human Immunodeficiency Virus (HIV) Antigen-Antibody Combination Assays: Evaluation of HIV Seroconversion Sensitivity and Subtype DetectionJournal of Clinical Microbiology, 2001
- Les tests de dépistage combiné de l'antigène p24 et des anticorps anti-VIH dans l'infection précoce à VIH-ITransfusion Clinique et Biologique, 2000
- Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assayJournal of Virological Methods, 1998